Business Wire

Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory

Share

Kinaset Therapeutics, Inc. (“Kinaset” or the “Company”), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Company also announced an exclusive global in-license and services agreement with Vectura Group plc (LSE: VEC) (“Vectura”) to develop and commercialize KN-002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in healthy volunteers and patients is poised to begin in the first half of 2021.

Kinaset is led by an experienced management team and Board of Directors with strong backgrounds in the development of respiratory therapeutics. The company is led by Chief Executive Officer Robert Clarke (formerly Pulmatrix, AIR/Alkermes), Chief Business Officer Roger Heerman (GlaxoSmithKline, Vectura), and Chief Development Officer Frazer Morgan (Vectura, 3M), each of whom has over 20 years of experience in the industry. Thomas B. King (Alexza, Vivus), Chairman of the Board, is joined on the Kinaset Board of Directors by founding investors Jamil Beg (5AM), Kevin Bitterman (Atlas), and Bram Vanparys (Gimv).

Kinaset is responsible for the overall development and commercialization of KN-002, with Vectura providing formulation development expertise and manufacturing of clinical trial supplies. The Company will pay Vectura fees for development services, certain regulatory and commercial milestones, and future royalties on global net sales in return for the license.

“I am excited to be part of Kinaset Therapeutics and their plans to deliver a next-generation therapeutic for the severe asthma population. The highly experienced management team and board coupled with the exclusive global license from Vectura provide a great springboard for the launch of Kinaset,” said Thomas B. King. He added “Vectura’s profile as a world-class CDMO with multiple approved inhaled therapeutics make them a trusted partner as we move KN-002 to our upcoming clinical trial.”

Robert Clarke, Ph.D., Chief Executive Officer, and a co-founder of Kinaset Therapeutics, commented on the company and the KN-002 program, “Our goal is to build Kinaset into a leading respiratory therapeutics company focused on patients starting with KN-002. Severe asthmatics continue to suffer from the limited availability of safe and effective treatment options. We believe that our inhaled pan-JAK inhibitor, KN-002, has the potential to be a best-in-class therapeutic for this population. In addition, KN-002 could be a less-invasive and more cost-effective alternative to currently approved parenteral biologicals used in the treatment of severe asthma.”

Jamil M. Beg, Partner at 5AM Ventures and Director at Kinaset, commented, “The field of respiratory drug development has made incredible strides over recent years. Biologics have validated immunomodulatory approaches and advanced the standard of care for patients. However, there remains a significant need and burden on patients, especially in the severe asthma population. We see KN-002 as having transformational potential for patients and are excited to support a dedicated team at Kinaset that is building the next leading respiratory disease company.”

Unmet Clinical Needs

Asthma is a complex and heterogeneous disease affecting over 300 million people worldwide, with approximately 10% of patients having severe asthma1,2. Subjects with severe uncontrolled asthma suffer from frequent exacerbations, compromised lung function, and a reduced quality of life1-3. This group is associated with a disproportionate number of asthma-related hospitalizations and accounts for approximately 50% of asthma-related costs.4,5

Multiple inflammatory pathways are implicated in the pathogenesis of asthma6-8. Eosinophilic asthma, characterized by elevated levels of blood eosinophils and fractional exhaled nitric oxide8, accounts for about two-thirds of patients with severe asthma8. Conversely, a large proportion of subjects do not exhibit an eosinophilic profile and suffer from an inadequate response to parenteral biologicals and oral corticosteroids resulting in a loss of asthma control1-3. Therefore, additional therapeutics to support these non-eosinophilic patients represent a significant need in asthma control.

About Kinaset Therapeutics, Inc.

At Kinaset Therapeutics, we intend to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma with a group of dedicated drug development experts working to bring the therapy forward. More information can be found at www.kinasettherapeutics.com.

About Vectura

Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation, and development capabilities to deliver a broad range of complex inhaled therapeutics.

For further information, please visit Vectura's website at www.vectura.com.

References:
1 Kupczyk M, Wenzel S. J Intern Med 2012;272:121–32.
2 Wenzel S. Am J Respir Crit Care Med. 2005; 172; 149–60.
3 Chung KF, Wenzel SE, Brozek JL, et al. Eur Respir J 2014; 43: 343–73.
4 Price D, Fletcher M, van der Molen T. NPJ Prim Care Respir Med 2014; 12; 24: 14009.
5 World Allergy Organization (WAO). (https://www.worldallergy.org/educational_programs/world_allergy_forum/anaheim2005/blaiss.php [Last accessed: September 2020])
6 Godar M, Blanchetot C, de Haard H, et al. MAbs. 2018; 10 (1): 34–45.
7 Peters MC, Mekonnen ZK, Yuan S, et al. J Allergy Clin Immunol. 2014; 133: 388–94.
8 Fahy JV. Nat Rev Immunol. 2015; 15: 57-65.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roger Heerman – Chief Business Officer
info@kinasettx.com
+1 508-858-5810

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye